Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation ...

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...

As we head into the new year, now is the time to look back on the activity seen in the pharma space in 2025 and consider what ...

Ipsen first looked to add an ADC to its portfolio via a deal that would have been worth up to $900m with Sutro Biopharma in ...

Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.

The JPM Healthcare Conference offers an early view of investor sentiment in the industry, but identifying the most relevant trends amid the noise can be challenging.